ESMO 2017 Prostate Cancer

Viewing 1-20 of 41 articles

ESMO 2017: 14 years of progress in mCRPC – New avenues for immunotherapy and precision medicine: Invited Discussant

ESMO 2017: Prostate Cancer Poster Discussion: Invited Discussant

ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide

ESMO 2017: Cabazitaxel followed by ADT improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A Randomized, Open Label, Phase III, Multicenter trial

ESMO 2017: Assessment of health-related quality of life in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 vs 25 mg/m2 in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC)

ESMO 2017: Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

ESMO 2017: Management of M0 Patient with Rising PSA: How can PET imaging help?

ESMO 2017: The M0 Patient with Rising PSA - Case Presentation: The clinical problem, a multi-disciplinary issue

ESMO 2017: A Phase II Clinical Trial of Radium-223 Activity in Patients with mCRPC with Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status (EXCAAPE)

ESMO 2017: Immune Checkpoint Inhibitors in Prostate Cancer

ESMO 2017: Therapeutic Vaccines in Prostate Cancer

ESMO 2017: Immunogenomics of Lethal Prostate Cancer

ESMO 2017: Basic immunobiology in Prostate Cancer

ESMO 2017: Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: results from the CABADOC randomized trial

ESMO 2017: Adding abiraterone for patients with high-risk prostate cancer (PCa) starting long-term ADT: Outcomes in non-metastatic (M0) patients from STAMPEDE

ESMO 2017: What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis

ESMO 2017: PRORADIUM: Prospective Multi-Centre Study of Prognostic Factors in Castration Resistant Prostate Cancer Patients Treated with Radium-223

ESMO 2017: First Interim Results of the Radium-223 REASSURE Observational Study: Analysis of Patient Characteristics and Safety by Use of Abiraterone and/or Enzalutamide

ESMO 2017: Outcomes of Prechemotherapy Abiraterone Acetate or Enzalutamide for mCRPC after ADT + Docetaxel or ADT alone for mHSPC

ESMO 2017: Indirect Comparison of Abiraterone Acetate and Docetaxel for Treatment of Metastatic “Hormone-Sensitive” Prostate Cancer

1
2
3

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.